Solstice Neurosciences
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2003-01-01
- Employees
- 51
- Market Cap
- -
- Website
- http://www.solsticeneuro.com
An Open Label Safety and Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) Injectable Solution in Patients With Cervical Dystonia
Phase 4
Completed
- Conditions
- Cervical Dystonia
- First Posted Date
- 2008-06-20
- Last Posted Date
- 2019-05-10
- Lead Sponsor
- Solstice Neurosciences
- Target Recruit Count
- 502
- Registration Number
- NCT00702754
A Multi-Center Study of MYOBLOC for the Treatment of Sialorrhea in Parkinson's Disease Patients
Phase 2
Completed
- Conditions
- Drooling
- Interventions
- Biological: Botulinum Toxin Type B (Myobloc)Biological: Matched placebo to Myobloc
- First Posted Date
- 2007-08-13
- Last Posted Date
- 2019-05-07
- Lead Sponsor
- Solstice Neurosciences
- Target Recruit Count
- 54
- Registration Number
- NCT00515437
- Locations
- 🇺🇸
Dr. Madhavi Thomas, Dallas, Texas, United States
🇺🇸Dr. Stephen Reich, Baltimore, Maryland, United States
🇺🇸Dr. James Sutton, Oxnard, California, United States
© Copyright 2025. All Rights Reserved by MedPath